Nav: Home

Study finds lower death rates for TAVR centers that do more procedures

April 03, 2019

DURHAM, N.C. - Hospitals that perform the highest volume of transcatheter-aortic valve replacement (TAVR) procedures have significantly lower mortality rates than centers that do fewer of the minimally invasive surgeries, according to an analysis by a collaboration that included the Duke Clinical Research Institute.

The finding, published April 3 in the New England Journal of Medicine, comes as the Centers for Medicare & Medicaid Services is reconsidering the procedure's coverage parameters, which established a center's volume as a key criterion for reimbursement.

Approved in 2011, TAVR is largely performed on older patients insured by Medicare, and has grown into a multi-billion-dollar annual industry. As the number of procedures has escalated and the technique and devices have evolved, questions arose over the necessity of volume standards for CMS coverage.

"What we found is that there is still a very real relationship with annual volume and 30-day mortality at the hospital level, even taking into account the new devices and the learning curve that new centers face in the first 12 months of initiating a program," said lead author and Duke cardiologist Sreekanth Vemulapalli, M.D.

"TAVR is different from most other cardiac procedures - it's not a single-person effort," Vemulapalli said. The procedure involves putting a replacement valve over a damaged aortic valve using a catheter rather than open-chest surgery, similar to the way a stent is placed in coronary arteries. "Patients are evaluated by a surgeon and an interventional cardiologist, and there is usually also a cardiac imaging specialist involved in the procedure. That team approach is very important, which is why we looked at the data from a hospital level."

Even so, the authors said, the relationship between higher TAVR volumes and lower mortality was also evident at the individual proceduralist level, suggesting that repeated practice does improve outcomes.

Vemulapalli and colleagues launched their analysis last summer after CMS announced it would reevaluate coverage criteria. Using a database called the Transcatheter Valve Registry -- which includes all of the commercial procedures in the United States, including those covered by Medicare -- the researchers focused on volumes and outcomes from 2015-2017.

This timeframe rooted out earlier procedures that used outdated techniques and devices. The researchers also removed a hospital's first 12 months of cases to account for the learning curve. More than 500 hospitals were included and segmented into four groups based on volume, from lowest to highest.

Among nearly 100,000 transfemoral TAVR cases included in the analysis, the researchers found that hospitals in the group with the lowest volume had the highest 30-day mortality rate, at 3.19 percent, compared to hospitals in the group with highest volumes at 2.66 percent. This represents a relative reduction in patient mortality of 19.45 percent between the lowest- and highest-volume centers.

"This was the most comprehensive analysis of the outcomes of more than 100,000 people recently receiving TAVR in the U.S.," said John Carroll, M.D., professor of medicine at the University of Colorado School of Medicine and director of Interventional Cardiology at the UCHealth University of Colorado Hospital.

"The results definitively reaffirm an inverse relationship between the volume of procedures and the risk of death following the procedure," added Carroll, who is also the vice-chair of the STS-ACC TVT Registry Steering Committee. "The study's conclusive data should be incorporated by CMS in their final coverage policy to provide Americans with the best results from this transformative non-surgical therapy for the increasingly common condition of aortic stenosis, one of the most serious valve disease problems."

"These findings suggest a clear relationship between the volume of TAVR procedures and death at 30 days, both at the hospital level and at the individual operator level, and should be factored into the CMS revised National Coverage Determination related to TAVR until a validated quality outcome metric can be established," said co-author Michael Mack, M.D. "This relationship held true even after eliminating the first 12 months, meaning this is not just a 'learning curve.'"
-end-
In addition to Vemulapalli, Carroll and Mack, study authors include Zhuokai Li, David Dai, Andrzej S. Kosinski, Dharam J. Kumbhani, Carlos Ruiz, Vinod H. Thourani, George Hanzel, Thomas G. Gleason, Howard C Herrmann, Ralph G. Brindis and Joseph E. Bavaria.

Funding for the study was provided by the Society of Thoracic Surgeons and American College of Cardiology through the National Cardiovascular Data Registry.

Duke University Medical Center

Related Medicare Articles:

Study: Medicare could overpay medicare advantage plans by $200 billion over ten years
Research conducted at University of California San Diego School of Medicine found that current trends in diagnostic coding for patient risk scores will lead to Medicare overpaying Medicare Advantage (MA) plans substantially through 2026-likely to the tune of hundreds of billions of dollars.
10,000 Medicare patients die in the seven days after discharge from the ED
Researchers found that, each year, about 10,000 generally healthy patients die in the seven days after discharge from the ED.
Hospitals in Medicare ACOs reduced readmissions faster
The Accountable Care Organization model of paying for health care appears to help reduce hospital readmissions among Medicare patients discharged to skilled nursing facilities, a new study suggests.
Highest out-of-pocket cancer spending for Medicare patients without supplement
Which Medicare beneficiaries shoulder the highest out-of-pocket costs after a cancer diagnosis?
Medicare's new way of paying hospitals could cause a bundle of problems for some
Hospitals that take care of the oldest, sickest and most complicated patients could suffer financially under the Medicare system's new approach to paying for some types of care, a new study finds.
Study examines opioid agonist therapy use in Medicare patients
Few Medicare enrollees appear to be receiving buprenorphine-naloxone, the only opioid agonist therapy for opioid addiction available through Medicare Part D prescription drug coverage, according to a study published online by JAMA Psychiatry.
Possible to account for disadvantaged populations in Medicare's payment programs
A new report from the National Academies of Sciences, Engineering, and Medicine says that Medicare's value-based payment programs could take into account social risk factors -- such as low socio-economic position, residence in disadvantaged neighborhoods, or race and ethnicity -- but any proposal to do so will entail both advantages and disadvantages that need to be carefully considered.
The association between Medicare eligibility and rehabilitative care
Researchers from the Center for Surgery and Public Health at BWH found that becoming Medicare eligible at age 65 (as compared to age 64) was associated with an abrupt 6.4 percentage-point decline in the number of people who were uninsured and a 9.6 percentage-point increase in rehabilitation.
Telemedicine use increases among rural Medicare beneficiaries
Telemedicine use in Medicare has been increasing rapidly, and in 2013 there were over 100,000 telemedicine visits for Medicare beneficiaries.
Study examines use of telemedicine among rural medicare beneficiaries
Although the number of Medicare telemedicine visits increased more than 25 percent a year for the past decade, in 2013, less than 1 percent of rural Medicare beneficiaries received a telemedicine visit, according to a study appearing in the May 10, 2016 issue of JAMA.

Related Medicare Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".